Medical/Pharmaceuticals
PharmaBlock CMC Lifecycle Strategy Forum: Smarter Decisions Across the Drug Development Lifecycle
Lifecycle-based CMC strategies can help biotech companies balance speed, risk and long-term asset value as programs advance globally NANJING, China, Nov. 9, 2026 /PRNewswire/ -- PharmaBlock hosted its CMC Lifecycle Strategy Forum in Nanjing on November 5 and 6, bringing together experienced phar...
2026-11-09 16:29
1562
Timing Affects Speed, Not Total Exposure
CureGene Presents Evategrel China–US PK/PD and Food-Effect Data at AHA 2026 SHANGHAI, Nov. 8, 2026 /PRNewswire/ -- Clopidogrel does not work the same way in every patient. In East Asian populations the gap is wider still: a share of patients get too little platelet inhibition at the standard dose...
2026-11-09 08:51
1238
Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy
* SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks of treatment with 150 mg Q2W/450 mg Q4W * SINTBILO® (tafolecimab injection) monotherapy significantly decreased non-HDL-C, vLDL-C, ApoB, and Lp(a) af...
2026-11-09 08:00
2544
VS Pharmtech Boosts Cancer Treatment Efficacy Without Adding Toxicity
SEOUL, South Korea, Nov. 6, 2026 /PRNewswire/ -- Cancer drugs keep improving, but their limits remain. When antibody therapies first emerged, only a fraction of patients benefited, and small-molecule anticancer drugs often carry severe toxicity. Rather than developing a new anticancer drug, Park ...
2026-11-07 01:00
4369
NORROY BIOSCIENCE Showcased 11 Research Presentations at EANM' 26, Advancing Radiopharmaceutical Innovation and Global Ecosystem Collaboration
WUXI, China, Nov. 5, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a late-stage clinical biotechnology company focused on innovative targeted radiopharmaceuticals, today announced that its proprietary pipelines were featured in eight Top Rated Oral Presentations (TROP) and three e-posters at ...
2026-11-05 18:00
2665
Dizal to Present Latest Clinical Data at ASH 2026
* Golidocitinib monotherapy showed high and durable response in adults with secondary HLH, to be featured in an oral presentation. * Two oral presentations showing superior clinical benefits of birelentinib, as a single agent or in combination with a BCL2 inhibitor, in 1st line CLL/SLL SHANGH...
2026-11-05 16:16
2324
Harbour BioMed Appoints Ms. Vivian Feng as Head of External Collaboration
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 5, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced t...
2026-11-05 14:57
2235
Ivonescimab Receives NMPA Priority Review for First-Line Biliary Tract Cancer
HONG KONG, Nov. 4, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) has been granted Priority Review by China's National Medical Products Adm...
2026-11-05 12:19
2820
ONE OF THE WORLD'S FIRST PERSONALISED BRAIN STIMULATION STUDIES SHOWS PROMISE FOR SEVERE OCD WITH NUH AND NUS MEDICINE EXTENDING THE APPROACH TO DEPRESSION AND ANXIETY
Building on an established NUH–NUS Medicine collaboration, the work combines clinical expertise and cutting‑edge neuroimaging to improve outcomes for patients who have not responded to standard treatments SINGAPORE, Nov. 4, 2026 /PRNewswire/ -- Mental health treatments such as transcranial magne...
2026-11-05 08:05
2229
Lunit Presents AI-Powered Pathology Research in Ovarian and Bladder Cancers at SITC 2026
Studies with Labcorp and CellCarta identify proliferation-related tissue differences in HRD ovarian cancer and explore spatial immune features associated with immunotherapy response in bladder cancer SEOUL, South Korea, Nov. 4, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI f...
2026-11-04 22:00
3183
Crystal Pharmatech Completes ELDICO ED-1 Installation; Dedicated MicroED Now in Routine Service
Instrument operational at the Suzhou R&D center, with MicroED built into solid-form screening and results in as little as 48 hours SUZHOU, China, Nov. 4, 2026 /PRNewswire/ -- Crystal Pharmatech, a science-driven CRO/CDMO specializing in solid-state research, preformulation studies, and formulati...
2026-11-04 20:15
1703
TJ Biopharma Announces Publication of Plonmarlimab Phase 2 Results in the Journal of Hematology & Oncology
* Findings build on TJ Biopharma's pioneering work on GM-CSF as a therapeutic target in macrophage- and myeloid cell-driven inflammation * Phase 2 results show encouraging clinical responses and glucocorticoid-sparing potential in macrophage activation syndrome HANGZHOU, China, Nov. 4, 2026 /...
2026-11-04 18:00
2885
Minghui Pharmaceutical and ASKA Pharmaceutical Enter into Exclusive License Agreement for the IGF-1R Antibody in Japan
HANGZHOU, China, SHANGHAI and TOKYO, Nov. 4, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui") and ASKA PharmaceuticalCo., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan. MHB018A is a no...
2026-11-04 14:30
3185
IASO Bio Hosts FUCASO Singapore Launch Event, Marking the Official Commercial Landing of China's Original Fully Human BCMA CAR-T Cell Therapy in Southeast Asia's Healthcare Hub
IASO Bio and its Singapore partner Pills and Pokes jointly hosted the FUCASO launch event in Singapore on November 3, marking the official commercial arrival of the world's first fully human BCMA-targeted CAR-T cell therapy in Singapore. FUCASO was approved by Singapore's Health Sciences Authorit...
2026-11-04 12:59
3126
WuXi Biologics Receives Double Honors at 2026 HERA for ESG Reporting and Environmental Excellence
HONG KONG, Nov. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced it received two Grand Awards at the ninth Hong Kong ESG Reporting Awards (HERA), winning Best ESG Report (Large-Cap) and Excell...
2026-11-04 12:44
2117
Samsung Biologics Achieves 'Negligible Risk' Rating in Sustainalytics ESG Assessment
* Earns ESG Risk Rating score of 9.0, ranking among the top 0.5% in the pharmaceuticals industry * Advances from 'Low Risk' to 'Negligible Risk,' the lowest ESG risk category * Recognition reflects continued improvements in ESG risk management across operations INCHEON, South Korea, Nov. 3, ...
2026-11-04 07:30
2663
Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition
The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across China HANGZHOU, China, Nov. 3, 2026 /PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions company in Asia, announced the strategic acqu...
2026-11-04 07:00
2078
MoleculeMind's New MMDesign Technical Report Demonstrates 94.7% Campaign Success Rate Across Diverse Molecular Targets and Modalities
SHANGHAI, Nov. 3, 2026 /PRNewswire/ -- MoleculeMind
2026-11-03 23:00
6031
140th Canton Fair Phase 3 Highlights Intelligent Healthcare Innovations for a Better Life
GUANGZHOU, China, Nov. 3, 2026 /PRNewswire/ -- Phase 3 of the 140th Canton Fair, held from October 31 to November 4, centers on the theme "Better Life." As health remains central to high quality of life, the Intelligent Healthcare Zone has emerged as a focal point for buyers seeking solutions tha...
2026-11-03 14:29
3574
POMDOCTOR LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing Requirements
GUANGZHOU, China, Nov. 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (Nasdaq: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on October 28, 2026, it received two letter...
2026-11-03 05:05
2563
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1169 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1130 media titles]
2026-11-05 06:52Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1118 media titles]
2026-11-06 22:06
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00NYSE Chair Sharon Bowen Earns Lifetime Achievement Award: NYSE Content Update
[Picked up by 1073 media titles]
2026-11-05 22:05
Most Read
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
63442
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
28648
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
22680
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
19583